There are currently 45 active clinical trials seeking participants for Brain Metastases research studies. The states with the highest number of trials for Brain Metastases participants are Michigan, California, New York and North Carolina.
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
NCT04955743
Recruiting
This is a phase 2, Simon's 2-stage designed study with 2 cohorts of anti-PD-1/PD-L1 experienced patients with untreated brain metastases: 1) melanoma and 2) renal cell carcinoma (RCC).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: Yale University, New Haven, Connecticut
Conditions: Melanoma, Renal Cell Carcinoma, Brain Metastases, PD1/PD-L1 Experienced, Pembrolizumab, Lenvatinib, Metastatic Melanoma
Register for Updates
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
NCT05419076
Recruiting
The purpose of the study is to see if stereotactic radiosurgery/SRS is an effective treatment for people with a new diagnosis of brain metastases from small cell lung cancer/SCLC.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/14/2024
Locations: Hartford Healthcare (Data Collection Only), Hartford, Connecticut +7 locations
Conditions: Lung Cancer, Lung Cancer Metastatic, Brain Metastases, Brain Metastases, Adult, Small-cell Lung Cancer, Small Cell Lung Carcinoma
Register for Updates
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
NCT03550391
Recruiting
Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding the surrounding normal brain. Whole brain radiation therapy with hippocampal avoidance (HA-WBRT) is when radiation therapy is given to the whole brain, while trying to decrease the amount of radiation that is delivered to the area of the hippocampus. The hipp... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona +83 locations
Conditions: Brain Metastases
Register for Updates
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
NCT05692635
Recruiting
The purpose of this research is to see if monitoring the brain using magnetic resonance imaging (MRI) after radiation therapy will allow investigators to find cancer that has spread to the brain (brain metastases) before it causes symptoms.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina
Conditions: Brain Metastases, Nonsmall Cell Lung Cancer Stage III
Register for Updates
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
NCT06322342
Recruiting
This Phase 2 trial will assess the safety, tolerability, efficacy, imaging pharmacodynamics, and pharmacokinetics of RVP-001, a novel manganese-based MRI contrast agent, at three escalating dose levels. RVP-001 will be administered as a single IV bolus to subjects with known gadolinium-enhancing central nervous system (CNS) lesions (for example stable brain tumor or multiple sclerosis) who have recently had a gadolinium-based contrast agent (GBCA)-enhanced MRI of the brain.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/12/2024
Locations: Yale New Haven Hospital, New Haven, Connecticut +3 locations
Conditions: Central Nervous System (CNS) Lesions, Brain Metastases, Brain Neoplasms, Brain Neoplasms, Benign, Brain Tumor, Primary, Brain Tumor, Recurrent, Brain Tumors, Brain Cancer, Brain Tumor, Brain Neoplasm, Primary, Multiple Sclerosis, Multiple Sclerosis Brain Lesion, Neurofibroma, Acoustic Neuroma, CNS Tumor, CNS Lesion, CNS Metastases, CNS Cancer, CNS Lymphoma
Register for Updates
Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)
NCT05700721
Recruiting
To learn if the combination of niraparib and dostarlimab can help to control advanced cancer that has spread to the brain.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/06/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Brain Metastases
Register for Updates
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
NCT03223922
Recruiting
This is a trial that evaluates the preservation of cognition and neuropsychiatric function following genu-sparing whole brain radiation in patients with brain metastases.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
06/05/2024
Locations: Sibley Memorial Hospital, Washington, District of Columbia +1 locations
Conditions: Brain Metastases
Register for Updates
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
NCT05559853
Recruiting
The purpose of this study is to develop and test a new magnetic resonance imaging (MRI) technique to see if it can be used to tell the difference between tumor growth from worsening of cancer and growth from the effects of treatment in participants who have brain tumors treated with radiation therapy called stereotactic radiosurgery (SRS).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/05/2024
Locations: Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
Conditions: Brain Metastases, Brain Metastases, Adult, Metastatic Brain Tumor, Metastatic Brain Cancer
Register for Updates
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
NCT05323955
Recruiting
Patients with advanced HER2+ breast cancer on maintenance trastuzumab/pertuzumab or T-DM1 with 1st or 2nd intracranial disease event (brain metastases) and stable extracranial disease will be enrolled. They will receive local therapy with stereotactic radiosurgery ± surgical resection if indicated followed by enrollment. Patients will continue standard of care trastuzumab/pertuzumab or T-DM1 with the addition of tucatinib. Hormone receptor positive patients requiring endocrine therapy should con... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +6 locations
Conditions: Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer
Register for Updates
REMASTer: REcurrent Brain Metastases After SRS Trial
NCT05124912
Recruiting
Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic radiosurgery (SRS), with or without surgery.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/23/2024
Locations: Duke University Hospital, Durham, North Carolina +2 locations
Conditions: Brain Metastases, Radiation Necrosis, Recurrent Tumor, Recurrent Metastases
Register for Updates
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
NCT03449238
Recruiting
Patients with metastatic breast cancer with at least 2 brain metastases will receive pembrolizumab every 3 weeks. Patients will undergo stereotactic radiosurgery (SRS) to one of the brain lesions. Pembrolizumab infusion will be given on Day 4 (+/-1) after SRS treatment at the standard dose of 200mg IV over 30 minutes and repeated every 3 weeks until disease progression or unacceptable toxicity.
Gender:
Female
Ages:
Between 19 years and 90 years
Trial Updated:
05/21/2024
Locations: Weill Cornell Medicine, New York, New York +2 locations
Conditions: Metastatic Breast Cancer, Brain Metastases
Register for Updates
Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases
NCT05789589
Recruiting
To determine the safety and efficacy of using the drug azeliragon combined with stereotactic radiosurgery. Specifically, to determine if this combination will lead to improved response in the brain (tumor shrinking in size) and overall tumor control (how long tumor remains controlled).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: Miami Cancer Institute at Baptist Health, Inc., Miami, Florida
Conditions: Cancer, Metastasis, Metastatic Cancer, Brain Metastases, Brain Metastases, Adult
Register for Updates